N/A N=31 Transcutaneous Vagus Nerve Stimulation (taVNS) Dosage Study 1
Healthy
Primary: Tolerability Measured by Tolerability Questionnaire — 2.2; 2.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=39 A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321
Healthy
Primary: Number of Subjects With Drug-related Adverse Events — 0; 1; 0; 0 Participants
Phase 1 N=18 Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART
HIV Vaccine · HIV-1-infection
Primary: Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE) — 12.5; 0; 0 percentage of participants
Phase 4 N=32 Angiotensin II in General Anesthesia
Hypertension
Primary: Median Dose Required to Increase the Systolic Blood Pressure (SBP) — 35; 43; 45 ng/kg/min
N/A N=100 Estradiol Effects on Alcohol Across the Menstrual Cycle
Alcohol Use, Unspecified
Primary: Attentional Bias (Early Follicular Phase) — 347.99; 355.02 milliseconds
N/A N=6 A Neuroprosthesis for Prolonged Standing After SCI Using Multi-Contact Peripheral Nerve Electrodes
Spinal Cord Injury · Paralysis · Tetraplegia
Primary: Average Standing Performance in Terms of Elapsed Standing Time for All Subjects. — 32.6 Minutes
N/A N=44 The Blueberry Study
Healthy
Primary: Phenolic Acid Metabolites Measured in Plasma and Urine After Dietary Intervention — 13; 0; 25; 3 Counts of metabolites
N/A N=20 Vitamin D Supplementation in Kidney Disease
Renal Dialysis · Vitamin D Deficiency
Primary: Change in Hip Flexor Strength — 20.34; 6.83 percent change
Phase 2 N=20 Effect of Benralizumab in Atopic Dermatitis
Dermatitis, Atopic · Dermatitis · Eczema
Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2
N/A N=20 Berries, Bugs, and the Blues
Depressive Symptoms
Primary: Depressive Symptom Severity — -5; -4 scores on a scale
Phase 1 N=10 Effect of Allopregnanolone on Stress-induced Craving
Alcohol Use Disorder
Primary: Alcohol Urge Questionnaire (AUQ) Pre-script — 24.45; 21.51; 19.15; 26.29 units on a scale
N/A N=11 Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer
Breast Cancer
Primary: Number of Participants With Implantable Devices — 3; 5; 1; 2 Participants
Phase 2 N=286 Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception
Contraception
Primary: The Primary Outcome Measure is Effectiveness as Calculated by the Pearl Index — 0.53; 1.41; 0.00 Pearl Index
Phase 1 N=23 A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 3; 2; 2; 3 Participants
Early Phase 1 N=9 Gynecological Sentinel Lymph Nodes CEUS
Cervical Carcinoma · Malignant Female Reproductive System Neoplasm · Vaginal Carcinoma
Primary: Number of Sentinel Lymph Nodes (SLNs) Identified by Lymphosonography as Well as Blue Dye or Positron Emission Tomography (PET)-Computed Tomography (CT) — 17 sentinel…